Latest Conference Articles

Acoramidis significantly lowers cardiovascular event risk in ATTR-CM, emphasizing the need for early diagnosis & treatment.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

New research links marijuana use to higher readmission and mortality rates in heart failure patients.

Recent studies reveal finerenone's superior benefits over traditional MRAs in heart failure, showing reduced mortality and hospitalization rates.

This discussion highlights 24-week findings on povorcitinib for those with moderate to severe hidradenitis suppurativa (HS).

This EADV 2025 interview featuring Linda Stein Gold, MD, highlights her team’s findings on icotrokinra versus placebo and versus deucravacitinib in psoriasis.

This interview at EADV 2025 features Mona Shahriari, MD, who highlighted recent findings on the drugs icotrokinra and povorcitinib in dermatology.

A compiled list of the 8 most exciting presentations scheduled for the Heart Failure Society of American Annual Scientific Meeting 2025.

A compilation of 14 trials presented as late-breaking data at EADV 2025 Congress.

New findings from the POSITIVE trial highlight tildrakizumab's effectiveness in enhancing quality of life for psoriatic disease patients.

Ruxolitinib cream shows promising results in prurigo nodularis, with significant symptom improvements and strong safety profiles.

These data from the ECZTRA 3 and ECZTEND trials highlight tralokinumab’s impact on patients with atopic dermatitis long-term.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.

Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

These late-breaking data at EADV highlight the impacts of ATI-2138, an oral small-molecule ITK/JAK3 inhibitor, on atopic dermatitis.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

In this analysis, the long-term cardiovascular safety of upadacitinib treatment for atopic dermatitis was highlighted.

These new data, presented at EADV, highlight remibrutinib’s impact on specific IgG autoantibody levels in individuals with chronic spontaneous urticaria (CSU).

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

New data reveals ritlecitinib's long-term effectiveness for alopecia areata, showing significant hair regrowth and sustained benefits in patients.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.